NCT02950168, NCT02951039.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11185023 | PMC |
| http://dx.doi.org/10.1177/10760296241260728 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Periprocedural Edoxaban Management and Clinical Outcomes in Patients Undergoing Transcatheter Cardiovascular Procedures in the EMIT-AF/VTE Program.
Clin Appl Thromb Hemost
June 2024
Department of Cardiovascular Sciences, University Hospitals (UZ) Leuven, Leuven, Belgium.
NCT02950168, NCT02951039.
View Article and Find Full Text PDFManagement of edoxaban therapy and clinical outcomes in patients undergoing major or nonmajor surgery: a subanalysis of the EMIT-AF/VTE study.
Thromb J
December 2023
Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.
Background: Optimising periprocedural management of direct oral anticoagulation in patients with atrial fibrillation on chronic treatment undergoing major surgeries is an important aspect of balancing the risk of surgery-related bleeding with the risk of thromboembolic events, which may vary by surgery type.
Methods: This subanalysis of the prospective EMIT-AF/VTE programme assessed periprocedural-edoxaban management, according to physicians' decisions, and bleeding and thromboembolic event rates in patients who underwent major vs. nonmajor surgeries.
Safety and Efficacy of Uninterrupted Oral Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation with Different Techniques.
J Clin Med
October 2023
Cardiology Unit, Luigi Sacco University Hospital, 20131 Milan, Italy.
Background: The safety and efficacy of an uninterrupted direct anticoagulation (DOAC) strategy during catheter ablation (CA) for atrial fibrillation (AF) has not been fully investigated with different ablation techniques.
Methods: We evaluated consecutive AF patients undergoing catheter ablation with three different techniques. All patients were managed with an uninterrupted DOAC strategy.
Periinterventional Management of Edoxaban in Major Procedures: Results from the DRESDEN NOAC REGISTRY.
TH Open
July 2023
Division of "Thrombosis and Hemostasis," Department of Medicine I, University Hospital "Carl Gustav Carus, " Technical University Dresden, Dresden, Germany.
Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for venous thromboembolism (VTE) treatment or stroke prevention in atrial fibrillation. Major surgical procedures are not uncommon in anticoagulated patients but data on perioperative edoxaban management are scarce. Using data from the prospective DRESDEN NOAC REGISTRY, we extracted data on major surgical procedures in edoxaban patients.
View Article and Find Full Text PDFPredictive Factors and Clinical Events Associated with Edoxaban Interruption and Heparin Bridging Strategy: EMIT-AF/VTE.
Clin Appl Thromb Hemost
November 2023
Global Specialty Medical Affairs, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA.
Patients treated with edoxaban may require diagnostic and therapeutic procedures that involve edoxaban interruption. Although heparin bridging strategies are not recommended, heparin is frequently used in clinical practice. However, whether heparin use decreases thromboembolic risk remains unclear, and the potential for increased periprocedural bleeding remains a concern.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!